Treatments · Entity Annotation Prototype (beta)

3articles mentioning treatments

3treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: Adoptive T cell therapy ×

Adoptive T cell therapy

This treatment is selected. Its supporting articles are shown below.

Adoptive T cell therapy3

Articles mentioning Adoptive T cell therapy

3 articles · page 1 of 1

314 Cytokine-cell conjugates for engineered T cell therapy

jitc · abstract · 2025-11-04 · 1 matching annotations

75.5%

Chimeric antigen receptor (CAR) T cell therapy adoptive T cell therapy blood cancers solid tumors Neo4 Neo4-conjugated Scripps Research Institute Scripps Animal Care and Use Program ACT

…Background Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of blood cancers, but its effi…

371 Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL

jitc · abstract · 2025-11-04 · 1 matching annotations

81.8%

adoptive T cell therapy lifileucel advanced melanoma Massachusetts General Hospital Dana-Farber/Harvard Cancer Center melanoma Mass General Cancer Center Tumor Cartography Center Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

…se to immune checkpoint blockade (ICB) cancer immunotherapy and adoptive T cell therapy,1 2 but the identity of the subpopulations of TIL critical for …

601 Assessment of CRISPR PD-1 edited tumor-infiltrating lymphocytes in infusion products for adoptive cell therapy in metastatic melanoma

jitc · abstract · 2025-11-04 · 1 matching annotations

79.6%

Adoptive T cell therapy metastatic melanoma CRISPR-Cas9 PD-1 targeting immune checkpoint inhibitors The Danish National Committee on Health Research Ethics PD-1-targeted CRISPR-Cas9

…Background Adoptive T cell therapy with expanded tumor-infiltrating lymphocytes (TILs) and PD-1 ta…

Browse treatments

Adoptive T cell therapy

Articles mentioning Adoptive T cell therapy

314 Cytokine-cell conjugates for engineered T cell therapy

371 Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL

601 Assessment of CRISPR PD-1 edited tumor-infiltrating lymphocytes in infusion products for adoptive cell therapy in metastatic melanoma